低温治疗用于惊厥性癫痫持续状态的神经保护
HYBERNATUS多中心RCT纳入270例接受机械通气的惊厥性癫痫持续状态危重患者,随机分为低温组(32–34°C持续24小时)加标准治疗或单纯标准治疗,268例纳入分析。主要终点90天良好功能结局(GOS=5)在低温组49%(67/138)vs 对照组43%(56/130),校正共同OR 1.22(95%CI 0.75–1.99,P=0.43),无显著差异。第1天进展为脑电图确诊癫痫持续状态的比例低温组11% vs 对照组22%(OR 0.40,95%CI 0.20–0.79,P=0.009)。其他次要终点无显著差异,低温组不良事件更频繁。
要点
- 惊厥性癫痫持续状态机械通气患者加用低温(32–34°C×24h)未显著改善90天良好功能结局(GOS=5:49% vs 43%,校正共同OR 1.22,95%CI 0.75–1.99,P=0.43)。
- 低温组第1天进展为脑电图确诊癫痫持续状态的比例低于对照组(11% vs 22%,OR 0.40,95%CI 0.20–0.79,P=0.009)。
- 90天死亡率、第1天难治性癫痫持续状态、超难治性癫痫持续状态(对全身麻醉抵抗)及90天功能后遗症等次要终点组间无显著差异。
- 低温组不良事件比对照组更频繁。
- 作者结论:在惊厥性癫痫持续状态患者中,标准治疗加低温与单纯标准治疗相比,90天结局无显著改善。
适用人群与场景
- 接受机械通气的惊厥性癫痫持续状态危重患者,多中心试验纳入270例,268例纳入分析。
诊断标准与关键阈值
- 主要终点良好功能结局定义为90天格拉斯哥结局量表(GOS)评分5分(范围1–5分,1分为死亡,5分为无或轻微神经功能缺损)。
处置流程与药物剂量
- 低温组在标准治疗基础上接受32–34°C低温持续24小时。
- 对照组仅接受标准治疗。
研究设计与关键结果
- 多中心随机对照试验,270例接受机械通气的惊厥性癫痫持续状态危重患者随机分组,268例纳入分析;低温组(32–34°C×24h加标准治疗)vs 单纯标准治疗。
- 主要终点90天GOS=5:低温组67/138(49%)vs 对照组56/130(43%),校正共同OR 1.22(95%CI 0.75–1.99,P=0.43),无显著差异。
- 第1天进展为脑电图确诊癫痫持续状态:低温组11% vs 对照组22%,OR 0.40(95%CI 0.20–0.79,P=0.009)。
- 90天死亡率、第1天难治性癫痫持续状态、超难治性癫痫持续状态(对全身麻醉抵抗)、90天功能后遗症等次要终点组间无显著差异。
- 不良事件低温组比对照组更频繁。
证据类型、等级与局限
- 多中心随机对照试验(HYBERNATUS,ClinicalTrials.gov NCT01359332),由法国卫生部资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在惊厥性癫痫持续状态患者中,标准治疗加低温与单纯标准治疗相比,90天结局无显著改善。
- 低温组不良事件更频繁,第1天脑电图确诊癫痫持续状态进展率更低(11% vs 22%)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Convulsive status epilepticus often results in permanent neurologic impairment. We evaluated the effect of induced hypothermia on neurologic outcomes in patients with convulsive status epilepticus.
METHODS: In a multicenter trial, we randomly assigned 270 critically ill patients with convulsive status epilepticus who were receiving mechanical ventilation to hypothermia (32 to 34°C for 24 hours) in addition to standard care or to standard care alone; 268 patients were included in the analysis. The primary outcome was a good functional outcome at 90 days, defined as a Glasgow Outcome Scale (GOS) score of 5 (range, 1 to 5, with 1 representing death and 5 representing no or minimal neurologic deficit). The main secondary outcomes were mortality at 90 days, progression to electroencephalographically (EEG) confirmed status epilepticus, refractory status epilepticus on day 1, "super-refractory" status epilepticus (resistant to general anesthesia), and functional sequelae on day 90.
RESULTS: A GOS score of 5 occurred in 67 of 138 patients (49%) in the hypothermia group and in 56 of 130 (43%) in the control group (adjusted common odds ratio, 1.22; 95% confidence interval [CI], 0.75 to 1.99; P=0.43). The rate of progression to EEG-confirmed status epilepticus on the first day was lower in the hypothermia group than in the control group (11% vs. 22%; odds ratio, 0.40; 95% CI, 0.20 to 0.79; P=0.009), but there were no significant differences between groups in the other secondary outcomes. Adverse events were more frequent in the hypothermia group than in the control group.
CONCLUSIONS: In this trial, induced hypothermia added to standard care was not associated with significantly better 90-day outcomes than standard care alone in patients with convulsive status epilepticus. (Funded by the French Ministry of Health; HYBERNATUS ClinicalTrials.gov number, NCT01359332 .).
参考来源
- Legriel S, Lemiale V, Schenck M, et al. Hypothermia for Neuroprotection in Convulsive Status Epilepticus. N Engl J Med. 2016. PMID: 28002714. doi:10.1056/NEJMoa1608193
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。